In a recent blog by SynbiCITE, the UK’s national centre for the commercialisation of synthetic biology, Synpromics is listed as one of 7 prominent players in the UK’s thriving synthetic biology sector .

Synpromics OBN Awards

Edinburgh, UK, 6th October 2017 / Synpromics is thrilled to announce they have been awarded Best Emerging UK Synthetic Biotech Company at the 9th Annual OBN Awards celebration last night. Synpromics was nominated on the strength of being the leader in gene control, improving human health by enabling safer, more effective cell and gene medicines through proprietary genomics, bioinformatics and intelligent data-driven design.

meeting on the mesa

David Venables, CEO of Synpromics, will sit on the panel ‘Gene Therapy: Building the gene medicine pipeline through next generation technologies’ on the 4th October at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa to be held October 4-6 in La Jolla, California.


Edinburgh, UK, 20th September 2017 / Synpromics Ltd, the leader in gene control, today announces a new research partnership with Solid Biosciences, LLC. Under the terms of the agreement, Synpromics will provide Solid Biosciences access to a set of key muscle-selective promoter candidates to be used in the development of new treatment options for Duchenne muscular dystrophy (DMD).


At this year’s Bioprocessing Summit, Dr Graham Whyteside presented on 'Inducible synthetic promoters for the production of gene therapy viral vectors'. Synpromics has developed a novel proprietary inducible expression platform that provides exquisite and tuneable control of gene expression.